(Q37306767)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18947259%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

review article

1 reference

title

New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18947259%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

0 references

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18947259%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

2

Stefania Maggi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18947259%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1

Angela M Abbatecola

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18947259%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

publication date

1 January 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18947259%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18947259%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18947259%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18947259%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

page(s)

913-925

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18947259%20AND%20SRC:MED&resulttype=core&format=json

Diabetes in elderly adults

25 December 2019

cites work

1 reference

https://api.crossref.org/works/10.2165%2F0002512-200825110-00002

Risk factors for falls in older disabled women with diabetes: the women's health and aging study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F0002512-200825110-00002

Frailty in older adults: evidence for a phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F0002512-200825110-00002

Geriatric conditions and disability: the Health and Retirement Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F0002512-200825110-00002

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F0002512-200825110-00002

Glucagon-like peptide-1 (7-37) augments insulin-mediated glucose uptake in elderly patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F0002512-200825110-00002

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F0002512-200825110-00002

Type 2 diabetes--therapy with dipeptidyl peptidase IV inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F0002512-200825110-00002

Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients

21 January 2018

1 reference

12 December 2020

1 reference

12 December 2020

A community survey of diabetes in the elderly

1 reference

12 December 2020

The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons

1 reference

12 December 2020

The role of vildagliptin in the management of type 2 diabetes mellitus

1 reference

12 December 2020

The prevalence of diabetic retinopathy among adults in the United States

1 reference

12 December 2020

Glucagon-like peptide 1 agonists and the development and growth of pancreatic beta-cells

1 reference

12 December 2020

Insulin resistance and risk of congestive heart failure

1 reference

12 December 2020

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

1 reference

12 December 2020

Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994.

1 reference

12 December 2020

Reported and measured physical functioning in older inner-city diabetic African Americans

1 reference

12 December 2020

Sarcopenic Obesity Predicts Instrumental Activities of Daily Living Disability in the Elderly

1 reference

12 December 2020

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

1 reference

12 December 2020

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

12 December 2020

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers

1 reference

12 December 2020

Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients

1 reference

12 December 2020

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

1 reference

12 December 2020

Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics.

1 reference

12 December 2020

Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects

1 reference

12 December 2020

Inhibition of gastric emptying by acarbose is correlated with GLP-1 response and accompanied by CCK release

1 reference

12 December 2020

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study

1 reference

12 December 2020

Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors

1 reference

12 December 2020

A Population-based Study of the Incidence of Complications Associated with Type 2 Diabetes in the Elderly

1 reference

12 December 2020

The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion

1 reference

12 December 2020

Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus

1 reference

12 December 2020

Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort

1 reference

12 December 2020

Diabetes and physical disability among older U.S. adults

1 reference

12 December 2020

Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose)

1 reference

12 December 2020

The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics

1 reference

12 December 2020

Alpha- and beta-cell interrelationships in health and disease

1 reference

12 December 2020

The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers

1 reference

12 December 2020

Microalbuminuria as predictor of increased mortality in elderly people

1 reference

12 December 2020

New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond

1 reference

12 December 2020

The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.

1 reference

12 December 2020

Management of type 2 diabetes mellitus in the elderly: special considerations

1 reference

12 December 2020

Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group.

1 reference

12 December 2020

The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes

1 reference

12 December 2020

Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus

1 reference

12 December 2020

Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas

1 reference

12 December 2020

Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.

1 reference

12 December 2020

Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

1 reference

12 December 2020

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

1 reference

12 December 2020

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

1 reference

12 December 2020

Glucagon-like peptide-1 response to acarbose in elderly type 2 diabetic subjects

1 reference

12 December 2020

Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes

1 reference

12 December 2020

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

1 reference

12 December 2020

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.

1 reference

12 December 2020

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial

1 reference

12 December 2020

Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

1 reference

12 December 2020

Patterns of disability related to diabetes mellitus in older women

1 reference

12 December 2020

Effects of 3 Months of Continuous Subcutaneous Administration of Glucagon-Like Peptide 1 in Elderly Patients With Type 2 Diabetes

1 reference

12 December 2020

Prevalence, expenditures, and complications of multiple chronic conditions in the elderly

1 reference

12 December 2020

Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable

1 reference

12 December 2020

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

1 reference

12 December 2020

Changes in cognitive abilities over a 4-year period are unfavorably affected in elderly diabetic subjects: results of the Epidemiology of Vascular Aging Study.

1 reference

12 December 2020

Management of diabetes in the elderly: a clinical perspective

1 reference

12 December 2020

Frailty in the elderly: contributions of sarcopenia and visceral protein depletion

1 reference

12 December 2020

Older women with diabetes have an increased risk of fracture: a prospective study

1 reference

12 December 2020

Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study

1 reference

12 December 2020

Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes

1 reference

12 December 2020

Cardiovascular risk factors and cognitive decline in middle-aged adults

1 reference

12 December 2020

Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.

1 reference

12 December 2020

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

12 December 2020

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

12 December 2020

alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients

1 reference

12 December 2020

Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system

1 reference

12 December 2020

Association of diabetes mellitus and dementia: the Rotterdam Study.

1 reference

12 December 2020

Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.

1 reference

12 December 2020

Prevalence and risk factors for urinary incontinence in women with type 2 diabetes and impaired fasting glucose: findings from the National Health and Nutrition Examination Survey (NHANES) 2001-2002.

1 reference

12 December 2020

Longitudinal prevalence of major eye diseases.

1 reference

12 December 2020

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

1 reference

12 December 2020

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy

1 reference

12 December 2020

Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines

1 reference

12 December 2020

Economic costs of diabetes in the US in 2002.

1 reference

12 December 2020

Glucagon-like peptide-1 (7-37) augments insulin release in elderly patients with diabetes

1 reference

12 December 2020

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

1 reference

12 December 2020

Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea).

1 reference

12 December 2020

Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea

1 reference

12 December 2020

Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy

1 reference

12 December 2020

Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes

1 reference

12 December 2020

Ageing and diabetes: implications for brain function

1 reference

12 December 2020

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

12 December 2020

Conceptualisation and measurement of frailty in elderly people

1 reference

12 December 2020

Diabetes and Incidence of Functional Disability in Older Women

1 reference

12 December 2020